Alle Studies

89ZR-CX-072-PET scan studie

5 mei 2021
 

AB04030

12 april 2021
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of Masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg...

AB11002

A prospective, multicenter, randomised, open-label, active controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor...

ACT

Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal...

ACT

6 mei 2021
Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal...

ACT NY ESO synoviosarcoom

12 april 2021
Samenvatting In het AVL is de TCR studie voor NY ESO pos synoviosarcoom patiënten open. Gemetastaseerde synoviosarcoom patiënten voor eerste lijns/tweedelijns behandeling kunnen geïncludeerd worden. Er is in...

AIPAC

Active Immunotherapy PAClitaxel: A multicentre, Phase IIb, randomized, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-31g fusion protein) or placebo as adjunctive...

ALT-GIST EORTC 1321

ALT-GIST: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST). EORTC study...

AMG 479

A phase 3, multicenter, randomized, double-blind, placebo controlled, trial of AMG 479 or placebo in combination with Gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas.

Archipelago – OncoLifeS

18 maart 2022
Studiecoördinator Gerrie Steursma en Kim Angerman Afdeling Medische Oncologie Tel: 69383 / 13707 Prof. Dr. A.K.L. Reyners Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: a.k.l.reyners@umcg.nl

ARTFORCE

12 april 2021
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE. A randomized study with concomitant cisplatin and standard or adaptive high dose radiotherapy for advanced head and neck...

Ave-short-trial

11 mei 2022
Een nationaal, multicenter, niet-geblindeerde doelmatigheids studie waarbij zes maanden avelumab onderhoudsbehandeling wordt gegeven aan patienten met een lokaal gevorderd of gemetastaseerde urotheelcarcinoom zonder ziekteprogressie na minimaal 4 kuren...

Beslisboom testis en AYA studies

13 januari 2022

BLU-667

12 april 2021
A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. Protocolnummer: BLU-667-1101 Eudract...

BLU-667 studie (named-patient programma)

Zie BEACON: NET – medullair schildkliercarcinoom – palliatief – BLU-667 studie (named-patient programma)

Breast Optical Imaging

Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A...

CA017-078

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab...

CA209-143

Phase IIb Study of Nivolumab in comb. with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) Protocolnummer: CA209143 Eudractnummer: 2013-003738-34 METc nummer: 2014525 Onderzoekscode: O118 ECG...